A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus
Language English Country Great Britain, England Media print-electronic
Document type Case Reports, Journal Article, Review
PubMed
28191663
DOI
10.1111/jcpt.12506
Knihovny.cz E-resources
- Keywords
- anti-TNF treatment, drug-induced lupus erythematosus, lupus-like syndrome, ustekinumab,
- MeSH
- Adalimumab administration & dosage adverse effects MeSH
- Anti-Inflammatory Agents administration & dosage adverse effects MeSH
- Adult MeSH
- Humans MeSH
- Psoriasis drug therapy pathology MeSH
- Severity of Illness Index MeSH
- Lupus Erythematosus, Systemic chemically induced MeSH
- Tumor Necrosis Factor-alpha antagonists & inhibitors MeSH
- Ustekinumab therapeutic use MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Review MeSH
- Names of Substances
- Adalimumab MeSH
- Anti-Inflammatory Agents MeSH
- Tumor Necrosis Factor-alpha MeSH
- Ustekinumab MeSH
WHAT IS KNOWN AND OBJECTIVE: Drug-induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti-TNF therapies have been found to be associated with a lupus-like syndrome, which is clinically distinct from classical drug-induced as well as idiopathic lupus erythematosus. CASE DESCRIPTION: We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment. The condition resolved after adalimumab cessation, and the patient was started on ustekinumab with good results. WHAT IS NEW AND CONCLUSION: Ustekinumab might be a useful treatment option for patients with a history of TNF-induced lupus-like syndrome.
References provided by Crossref.org
